GW843682, 5-(5,6-Dimethoxy-1H-benzimidazol-1-yl)-3-{[2-(trifluoromethyl)-benzyl]oxy}thiophene-2-carboxamide
| Title | Journal |
|---|---|
| Identification of potent Yes1 kinase inhibitors using a library screening approach. | Bioorganic & medicinal chemistry letters 20130801 |
| Raptor, a positive regulatory subunit of mTOR complex 1, is a novel phosphoprotein of the rDNA transcription machinery in nucleoli and chromosomal nucleolus organizer regions (NORs). | Cell cycle (Georgetown, Tex.) 20110915 |
| An in-vitro evaluation of the polo-like kinase inhibitor GW843682X against paediatric malignancies. | Anti-cancer drugs 20110701 |
| Targeting Plk1 in cutaneous T-cell lymphomas (CTCLs). | Cell cycle (Georgetown, Tex.) 20110515 |
| Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis. | Cell cycle (Georgetown, Tex.) 20110415 |
| Polo-like kinase 1 regulates activation of AMP-activated protein kinase (AMPK) at the mitotic apparatus. | Cell cycle (Georgetown, Tex.) 20110415 |
| Polo-like kinase 1 enhances survival and mutagenesis after genotoxic stress in normal cells through cell cycle checkpoint bypass. | Carcinogenesis 20100501 |
| Polo-like kinase guides cytokinesis in Trypanosoma brucei through an indirect means. | Eukaryotic cell 20100501 |
| A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies. | Leukemia 20090901 |
| Design of potent thiophene inhibitors of polo-like kinase 1 with improved solubility and reduced protein binding. | Bioorganic & medicinal chemistry letters 20090315 |
| Discovery of thiophene inhibitors of polo-like kinase. | Bioorganic & medicinal chemistry letters 20090201 |
| Evaluation of Polo-like Kinase 1 inhibition on the G2/M checkpoint in Acute Myelocytic Leukaemia. | European journal of pharmacology 20080904 |
| In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1. | Molecular cancer therapeutics 20070201 |